Navigation Links
PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014
Date:7/28/2014

INCLINE VILLAGE, Nev., July 28, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2014 financial results for the period ended June 30, 2014, on Monday, August 11, 2014, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results.  A slide presentation relating to the call will be available via the webcast link on the PDL website.

Conference Call Details
To access the live conference call via phone, please dial (800) 668-4132 from the United States and Canada or (224) 357-2196 internationally. The conference ID is 79689642. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through August 19, 2014, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 79689642.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma, Inc.
PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue. PDL is currently focused on intellectual property asset management, acquiring new income generating assets, and maximizing value for its shareholders.

The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada.

In 2011, PDL initiated a strategy to bring in new income generating assets from the healthcare sector. To accomplish this goal, PDL seeks to provide non-dilutive growth capital and financing solutions to late stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL continues to pursue this strategic initiative for which it has already deployed approximately $715 million to date. PDL is focused on the quality of the income generating assets and potential returns on investment.

For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Logo - http://photos.prnewswire.com/prnh/20110822/SF55808LOGO


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
5. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. S1 Biopharma Expands Focus to Include Male Sexual Health
8. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, 2017 /PRNewswire/ ... "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company developing ... announced that data from its successful Phase 2a study ... treatment for localized prostate cancer, will be presented as ... nd Annual European Association of Urology in ...
(Date:3/23/2017)... 2017  Ethicon* today announced the completion of ... held medical device company that manufactures and markets ... treatment of Gastroesophageal Reflux Disease (GERD). This acquisition ... portfolio of minimally invasive options for patients suffering ... of the transaction have not been disclosed. ...
(Date:3/23/2017)... LITTLE SILVER, N.J. , March 23, 2017 ... device company, today announced that it has kicked ... in-growth into their 3D printed bone segments. ... of Engineering, "Our unique variable honeycomb lattice structures ... bone in-growth as compared to current allograft wedges ...
Breaking Medicine Technology:
(Date:3/23/2017)... New York, NY (PRWEB) , ... March 23, 2017 , ... 82% of adults are ... every 3 kids do not brush their teeth the minimum two times a day that ... teeth; with students missing 51 million hours of school and adults missing 164 million hours ...
(Date:3/23/2017)... Los Angeles, CA (PRWEB) , ... March 23, ... ... Series A funding investment in Los Angeles based healthcare technology company California Healthcom ... group’s portfolio into the US, and healthcare arena. With headquarters in California, CHG ...
(Date:3/23/2017)... ... 2017 , ... After raising more than $1.135 million ($1,479,231 AUD) from nearly ... in crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle ... , “We’re excited to be operating on U.S. shores, where most of our initial ...
(Date:3/23/2017)... ... 23, 2017 , ... According to the National Sleep Foundation , poor ... the only cause of the sunken-eye look, which can include dark circles or bags ... poor health are likely due to genetics, dehydration, allergies, and losing fat beneath the ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality Assurance ... Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. , ... only to the association, but also to the Health Care Quality and Patient Safety ...
Breaking Medicine News(10 mins):